Search results
May 20, 2024 · Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome ...
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
A high-level overview of Syros Pharmaceuticals, Inc. (SYRS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
3 days ago · SYRS Earnings Date and Information. Syros Pharmaceuticals last released its earnings data on May 14th, 2024. The reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals has generated ($5.01) earnings per share over the last year ( ($5.01) diluted earnings per share).
2 days ago · The Syros Pharmaceuticals stock price gained 2.00% on the last trading day (Friday, 31st May 2024), rising from $5.00 to $5.10. During the last trading day the stock fluctuated 6.43% from a day low at $4.82 to a day high of $5.13. The price has been going up and down for this period, and there has been a -6.93% loss for the last 2 weeks.
Find the latest Syros Pharmaceuticals, Inc. (SYRS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.
May 24, 2024 · Stock Price Forecast. The 2 analysts with 12-month price forecasts for SYRS stock have an average target of 14, with a low estimate of 13 and a high estimate of 15. The average target predicts an increase of 181.69% from the current stock price of 4.97.
